SCHEMBL3389480

SCHEMBL3389480

CC(C)(C)OC(=O)NCCCNC(=O)C1CCC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 1/20 0.53
EPHX1 P07099 1/20 0.51
NAAA Q02083 1/20 0.50
MEN1 O00255 1/20 0.50
GAA P10253 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
BTK Q06187 1/20 0.47
MAOA P21397 1/20 0.47
MAOB P27338 1/20 0.47
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA9 Q16790 2/20 0.44
ITGB3 P05106 4/20 0.43
ITGA2B P08514 4/20 0.43
STK17B O94768 1/20 0.43
STK17A Q9UEE5 1/20 0.43
FPR3 P25089 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28605405 0.87 GNAI3 (0.57) TDP1EPHX1NAAAMEN1GAA
SCHEMBL17623586 0.85 TDP1 (0.48) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL569251 0.81 TDP1 (0.74) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL745045 0.81 EPHX1 (0.54) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL13419014 0.80 GNAI3 (0.52) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL15945377 0.79 SMN1; SMN2 (0.53) TDP1EPHX1NAAAMEN1GAA
SCHEMBL13002619 0.79 EPHX1 (0.49) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL13920157 0.79 TDP1 (0.50) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL18282365 0.79 TDP1 (0.50) TDP1EPHX1MEN1GAAKMT2A
SCHEMBL3387935 0.79 NAAA (0.44) TDP1NAAAKMT2ASMN1; SMN2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983081-B1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2026-03-11 EP disclosed
US-20260007668-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS LLC (US) 2026-01-08 US disclosed
US-12377097-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2025-08-05 US disclosed
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2023-10-26 US disclosed
US-11590134-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof DECIPHERA PHARMACEUTICALS, LLC (US) 2023-02-28 US disclosed
EP-3983081-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF Deciphera Pharmaceuticals, LLC (US) 2022-04-20 EP disclosed
US-20100056524-A1 Compound MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-03-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056524-A1 Compound NR3C2, NR3C1, NR2E3 TDP1 4821/4885EPHX1 2806/4885NAAA 4405/4885
US-12377097-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 TDP1 645/4885EPHX1 3596/4885NAAA 1803/4885
US-11590134-B2 Aminopyrimidine amide autophagy inhibitors and methods of use thereof BECN1, SQSTM1, ATG7 TDP1 645/4885EPHX1 3596/4885NAAA 1803/4885
US-20260007668-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 TDP1 480/4885EPHX1 4431/4885NAAA 3821/4885
US-20230338376-A1 AMINOPYRIMIDINE AMIDE AUTOPHAGY INHIBITORS AND METHODS OF USE THEREOF BECN1, SQSTM1, ATG7 TDP1 645/4885EPHX1 3596/4885NAAA 1803/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.